Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Su Yeong | - |
dc.contributor.author | Kong, Min Gyu | - |
dc.contributor.author | Moon, Inki | - |
dc.contributor.author | Park, Hyun Woo | - |
dc.contributor.author | Choi, Hyung-Oh | - |
dc.contributor.author | Seo, Hye Sun | - |
dc.contributor.author | Cho, Yoon Haeng | - |
dc.contributor.author | Lee, Nae-Hee | - |
dc.contributor.author | Lee, Kwan Yong | - |
dc.contributor.author | Jang, Ho-Jun | - |
dc.contributor.author | Kim, Je Sang | - |
dc.contributor.author | Choi, Ik Jun | - |
dc.contributor.author | Suh, Jon | - |
dc.date.accessioned | 2023-12-14T06:31:05Z | - |
dc.date.available | 2023-12-14T06:31:05Z | - |
dc.date.issued | 2023-08 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.issn | 2005-6648 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25457 | - |
dc.description.abstract | Background/Aims: We aimed to analyze the efficacy of angiotensin receptorneprilysin inhibitor (ARNI) by the disease course of heart failure (HF). Methods: We evaluated 227 patients with HF in a multi-center retrospective cohort that included those with left ventricular ejection fraction (LVEF) & LE; 40% undergoing ARNI treatment. The patients were divided into patients with newly diagnosed HF with ARNI treatment initiated within 6 months of diagnosis (de novo HF group) and those who were diagnosed or admittedfor HF exacerbation for more than 6 months prior to initiation of ARNI treatment (prior HF group). The primary outcome was a composite of cardiovascular death and worsening HF, including hospitalization or an emergency visit for HF aggravation within 12 months.Results: No significant differences in baseline characteristics were reported between the de novo and prior HF groups. The prior HF group was significantly associated with a higher primary outcome (23.9 vs. 9.4%) than the de novo HF group (adjusted hazard ratio 2.52, 95% confidence interval 1.06-5.96, p = 0.036), although on a higher initial dose. The de novo HF group showed better LVEF improvement after 1 year (12.0% vs 7.4%, p = 0.010). Further, the discontinuation rate of diuretics after 1 year was numerically higher in the de novo group than the prior HF group (34.4 vs 18.5%, p = 0.064).Conclusions: The de novo HF group had a lower risk of the primary composite outcome than the prior HF group in patients with reduced ejection fraction who were treated with ARNI. | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.title | Clinical efficacy of angiotensin receptor-neprilysin inhibitor in de novo heart failure with reduced ejection fraction | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3904/kjim.2023.065 | - |
dc.identifier.scopusid | 2-s2.0-85170295257 | - |
dc.identifier.wosid | 001060394100001 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.38, no.5, pp 692 - 703 | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 38 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 692 | - |
dc.citation.endPage | 703 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | J-CURVE | - |
dc.subject.keywordAuthor | Angiotensin receptor-neprilysin inhibitor | - |
dc.subject.keywordAuthor | Heart failure | - |
dc.subject.keywordAuthor | Clinical outcome | - |
dc.subject.keywordAuthor | Cardiac reverse remodeling | - |
dc.subject.keywordAuthor | Worsening heart failure | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.